Antibiotic Ceftin Sodium with Treatment and Prophylaxis of Infection

Model NO.: DAWACSW0001 Usage Mode: I.V / I.M State: Solid Type: Biological Products Name: Ceftin Sodium for Injection OEM: Acceptable Trademark: GUYENNE Origin: France Application: Internal Medicine Suitable for: Elderly, Children, Adult Shape: Powder Pharmaceutical Technology: Chemical Synthesis Administration Route: I.V / I.M MOQ: 1 Box Specification: 0.75g Antibiotic Cefuroxme Sodium With Treatment Of Infection
 

Specificathion	0.75g
Package	1vial+1amp/tray/box

Cefuroxme is a white to faintly yellow powder to which appropriate amounts of water are added to prepare
an off-white suspension for intramuscular use or a yellow solution for intravenous administration. Variations
in the intensity of this colour do not indicate any change in either the efficacy or safety of the product.

Indications
Cefuroxme is a bactericidal cephalosporin antibiotic which is resistant to most β-lactamases and is active
against a wide range of Gram-positive and Gram-negative organisms.

It is indicated for the treatment of infections before the infecting organism has been identified or when
caused by sensitive bacteria. Susceptibility to cefuroxme sodium will vary with geography and time and local
susceptibility data should be consulted where available.

Indications include:
• Respiratory tract infections for example, acute and chronic bronchitis, infected bronchiectasis, bacterial
  pneumonia, lung abscess and post-operative chest infections.
• Ear, nose and throat infections for example, sinusitis, tonsillitis, pharyngitis and otitis media.
• Urinary tract infections for example, acute and chronic pyelonephritis, cystitis and asymptomatic
  bacteriuria.
• Soft-tissue infections for example, cellulitis, erysipelas and wound infections.
• Bone and joint infections for example, osteomyelitis and septic arthritis.
• Obstetric and gynaecological infections, pelvic inflammatory diseases.
• Gonorrhoea particularly when penicillin is unsuitable.
• Other infections including septicaemia, meningitis and peritonitis.
• Prophylaxis against infection in abdominal, pelvic, orthopaedic, cardiac, pulmonary, oesophageal and
  vascular surgery where there is increased risk from infection.

Usually cefuroxme will be effective alone, but when appropriate it may be used in combination with an
aminoglycoside antibiotic, or in conjunction with metronidazole (orally or by suppository or injection),
especially for prophylaxis in colonic or gynaecological surgery (see Pharmaceutical Precautions).

Where appropriate cefuroxme sodium is effective when used prior to oral therapy with cefuroxme axetil in
the treatment of pneumonia and acute exacerbations of chronic bronchitis.

Dosage and Administration
Cefuroxme for Injection - for intravenous (IV) and/or intramuscular (IM) administration.
No more than 750 mg should be injected at one intramuscular site.

General Recommendations
Adults
Many infections respond to 750 mg three times daily by intramuscular or intravenous injection. For more
severe infections the dose should be increased to 1.5 g three times daily given intravenously. The frequency
of administration may be increased to 6-hourly if necessary, giving total daily doses of 3 to 6 g. Where
clinically indicated, some infections respond to 750 mg or 1.5 g twice daily (intravenously or intramuscularly)
followed by oral therapy with cefuroxme axetil.

Infants and Children
30 to 100 mg/kg/day given as 3 or 4 divided doses. A dose of 60 mg/kg/day is appropriate for most
infections.

Neonates
30 to 100 mg/kg/day given as 2 or 3 divided doses (see Pharmacokinetic Properties).

Gonorrhoea
Adults
1.5 g as a single dose (as 2 x 750 mg Injections given intramuscularly with different sites, e.g. each buttock).

Meningitis
Cefuroxme is suitable for sole therapy of bacterial meningitis due to sensitive strains.

Adults
3 g given intravenously every eight hours.

Infants and Children
150 to 250 mg/kg/day given intravenously in 3 or 4 divided doses.

Neonates
The dosage should be 100 mg/kg/day given intravenously.

Prophylaxis
Adults
The usual dose is 1.5 g given intravenously with induction of anaesthesia for abdominal, pelvic and
orthopaedic operations. This may be supplemented with two 750 mg intramuscular doses 8 and 16 hours
later.

In cardiac, pulmonary, oesophageal and vascular operations, the usual dose is 1.5 g given intravenously
with induction of anaesthesia, continuing with 750 mg given intramuscularly three times daily for a further 24
to 48 hours.

In total joint replacement, 1.5 g cefuroxme powder may be mixed dry with each pack of methyl methacrylate
cement polymer before adding the liquid monomer.

Sequential Therapy
Adults
Duration of both parenteral and oral therapy is determined by the severity of the infection and the clinical

status of the patient.
Pneumonia: 1.5 g cefuroxme three times daily or twice daily (given intravenously or intramuscularly) for 48
to 72 hours, followed by 500 mg twice daily cefuroxme axetil oral therapy for 7 to 10 days.

Acute Exacerbations of Chronic Bronchitis: 750 mg cefuroxme three times daily or twice daily (given
intravenously or intramuscularly) for 48 to 72 hours, followed by 500 mg twice daily cefuroxme axetil oral
therapy for 5 to 10 days.




 

Contact us if you need more details on Cephalosporin. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Ceftriaxone、Zinacef. If these products fail to match your need, please contact us and we would like to provide relevant information.

Product Categories : Antibiotics